Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

Patients Getting Weight Loss Information from Advertising as Opposed to Doctors: New Study Suggests ...

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous ...

Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses new real-world data showing that most high-risk ...

What was once considered a competitive advantage for forward-thinking commercial teams has now become essential for success ...

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at ...